To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Pegylated-fibroblast growth factor 21 (BMS-986036)

Invented name: NA

Latest Decision number(s): 1) P/0346/2021

P/ Corresponding PIP number(s): 1) EMEA-002448-PIP01-18-M02

Date of initial marketing authorisation granted: NA

Date of authorisation of new indication, pharmaceutical form or route of administration: NA

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of non-alcoholic steatohepatitis (NASH) / Treatment of NASH with moderate to severe liver fibrosis

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☒ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☒ other reason (please specify: Evolution of the company's strategic focus)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

As a result of a strategic review of development programs in fibrosis, Bristol Myers Squibb (BMS) has decided no longer to focus on the pegbelfermin (BMS-986036) program for NASH. Therefore, BMS will not be advancing pegbelfermin to Phase 3 development. BMS will complete any remaining clinical development activities and is exploring external opportunities for pegbelfermin. This decision was not

based on any observed, expected, or perceived safety finding. Rather, this decision is consistent with the evolution of the company's strategic focus.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point:	Signature on file
Date:	22 June 2022

Contact for inquiries from interested parties:	Bristol-Myers Squibb International Corporation
Telephone:	+44 1423 533 610
Email:	medical.information@bms.com